Posted on 05/06/2023 1:49:36 PM PDT by bitt
A recent phase three study conducted by Eli Lilly examined the safety and efficacy of the study drug donanemab in participants with early Alzheimer's disease (AD).
The pharmaceutical company Eli Lilly announced in a press release on May 3, 2023, that a clinical trial of the experimental Alzheimer's drug, donanemab, showed it could significantly slow the progress of cognitive decline, allowing patients increased independence.
The drugmaker's announcement revealed that the drug succeeded in halting early AD progression in nearly half of the participants, slowing cognitive decline rates by 35% compared to control participants.
Donanemab is an antibody that targets protein aggregates, known as amyloid beta proteins, which are the causative agents of brain plaques. Despite the direct causes of Alzheimer's being unknown, brain plaques have been thought to slow brain function and thus advance cognitive decline.
If the therapy were approved by the Food and Drug Administration (FDA), it would become the third Alzheimer’s drug to enter the market in the past three years. Safety concerns remain despite the promising trial results, with at least two participants experiencing fatal brain swelling.
(Excerpt) Read more at news-medical.net ...
My guess is this drug really does nothing and I would need to see the trial data in detail since I believe nothing from these people anymore and what will the price be, well the latest one on the market is $60,000 a year.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.